NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: The Atherosclerosis Risk in Communities study

Pharmacogenetics and Genomics

Volumn 16, Issue 12, 2006, Pages 891-899

  Lee, Craig R ^a,b   North, Kari E ^c   Bray, Molly S ^d   Avery, Christy L ^c   Mosher, Mary Jane ^c   Couper, David J ^c   Coresh, Josef ^e   Folsom, Aaron R ^f   Boerwinkle, Eric ^d   Heiss, Gerardo ^c   Zeldin, Darryl C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Coronary artery disease; Endothelial nitric oxide synthase; Polymorphism; Smoking; Stroke

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CELL FUNCTION; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AFRICAN AMERICANS; ALLELES; BASE SEQUENCE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CORONARY DISEASE; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; UNITED STATES;

EID: 33751085882     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000236324.96056.16     Document Type: Article

References (31)

1. American Heart Association. Heart disease and stroke statistics-2004 update. Dallas, TX; 2003.
2. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 6:653-658.
3. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 22:2805-2809.
4. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 12:2061-2071.
5. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 1:60-68.
6. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000; 4:451-458.
7. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 6:998-1005.
8. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 10:1731-1737.
9. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 16:1905-1910.
10. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 18:2342-2347.
11. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, et al. Replication protein a1 reduces transcription of the endothelial nitric oxide synthase gene containing a - 786T → C mutation associated with coronary spastic angina. Hum Mol Genet 2000; 18:2629-2637.
12. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate versus Glutamate at position 298. Proc Natl Acad Sci USA 2000; 6:2832-2835.
13. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 11:1359-1365.
14. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial no synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 2002; 5:e1-e4.
15. Nakayama M, Yoshimura M, Sakamoto T, Shimasaki Y, Nakamura S, Ito T, et al. Synergistic interaction of T-786 → C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 2003; 11:683-688.
16. Nasreen S, Nabika T, Shibata H, Moriyama H, Yamashita K, Masuda J, et al. T-786C polymorphism in endothelial no synthase gene affects cerebral circulation in smokers: possible gene-environmental interaction. Arterioscler Thromb Vasc Biol 2002; 4:605-610.
17. Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 11:1153-1158.
18. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 1989; 4:687-702.
19. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study: methods and initial two years' experience. J Clin Epidemiol 1996; 2:223-233.
20. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999; 4:736-743.
21. The National Survey of Stroke. National Institute of Neurological and Communicative Disorders and Stroke. Stroke 1981; 2(Pt 2 Suppl 1):I1-91.
22. Bray MS, Boerwinkle E, Doris PA. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 2001; 4:296-304.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 2:263-265.
24. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 12:1165-1172.
25. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 5:1162-1169.
26. Li R, Folsom AR, Sharrett AR, Couper D, Bray M, Tyroler HA. Interaction of the glutathione S-transferase genes and cigarette smoking on risk of lower extremity arterial disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001; 3:729-738.
27. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
28. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 16:9440-9445.
29. Sofowora G, Dishy V, Xie HG, Imamura H, Nishimi Y, Morales CR, et al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 9:809-814.
30. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smokingdependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 1:41-45.
31. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) study. JAMA 1998; 2:119-124.